[Mutation Pedigree and Treatment Selection of Erdheim-Chester Disease]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2023 Dec 4

PMID 38049347

Authors

M Lang

D B Zhou

X X Cao

Affiliations

Soon will be listed here.

References

Emile J, Diamond E, Helias-Rodzewicz Z, Cohen-Aubart F, Charlotte F, Hyman D . Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014; 124(19):3016-9. PMC: 4224196. DOI: 10.1182/blood-2014-04-570937. View

Bonnet P, Chasset F, Moguelet P, Abisror N, Itzykson R, Bouaziz J . Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation. Haematologica. 2019; 104(11):e530-e533. PMC: 6821636. DOI: 10.3324/haematol.2019.223552. View

Gianfreda D, Nicastro M, Galetti M, Alberici F, Corradi D, Becchi G . Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood. 2015; 126(10):1163-71. DOI: 10.1182/blood-2015-01-620377. View

Ruan G, Goyal G, Shah M, Cohen-Aubart F, Amoura Z, Straetmans N . Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease: A Report From 2 Tertiary Referral Centers. Pancreas. 2020; 50(1):e6-e8. DOI: 10.1097/MPA.0000000000001704. View

Abeykoon J, Lasho T, Dasari S, Rech K, Ranatunga W, Manske M . Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease. Am J Hematol. 2022; 97(3):293-302. PMC: 9536810. DOI: 10.1002/ajh.26441. View

Ozkaya N, Rosenblum M, Durham B, Pichardo J, Abdel-Wahab O, Hameed M . The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol. 2017; 31(4):581-597. PMC: 6718953. DOI: 10.1038/modpathol.2017.160. View

Cao X, Niu N, Sun J, Cai H, Wang F, Wang Y . Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease. Orphanet J Rare Dis. 2019; 14(1):11. PMC: 6327591. DOI: 10.1186/s13023-018-0988-y. View

Haroche J, Amoura Z, Charlotte F, Salvatierra J, Wechsler B, Graux C . Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood. 2008; 111(11):5413-5. DOI: 10.1182/blood-2008-03-148304. View

Estrada-Veras J, OBrien K, Boyd L, Dave R, Durham B, Xi L . The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017; 1(6):357-366. PMC: 5446206. DOI: 10.1182/bloodadvances.2016001784. View

10.

Berti A, Cavalli G, Guglielmi B, Biavasco R, Campochiaro C, Tomelleri A . Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology. 2017; 6(6):e1318237. PMC: 5486186. DOI: 10.1080/2162402X.2017.1318237. View

11.

Tan A, Yzer S, Atebara N, Marr B, Verdijk R, Dalm V . Three Cases of Erdheim-Chester Disease With Intraocular Manifestations: Imaging and Histopathology Findings of a Rare Entity. Am J Ophthalmol. 2017; 176:141-147. DOI: 10.1016/j.ajo.2017.01.017. View

12.

Mayr M, Zojer N, Mirzaei S, Chott A . [Rare differential diagnosis in bilateral gonalgia]. Pathologie (Heidelb). 2022; 43(6):449-453. DOI: 10.1007/s00292-022-01095-z. View

13.

Diamond E, Durham B, Haroche J, Yao Z, Ma J, Parikh S . Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discov. 2015; 6(2):154-65. PMC: 4744547. DOI: 10.1158/2159-8290.CD-15-0913. View

14.

Cives M, Simone V, Rizzo F, Dicuonzo F, Lacalamita M, Ingravallo G . Erdheim-Chester disease: a systematic review. Crit Rev Oncol Hematol. 2015; 95(1):1-11. DOI: 10.1016/j.critrevonc.2015.02.004. View

15.

Franconieri F, Martin-Silva N, de Boysson H, Galateau-Salle F, Emile J, Bienvenu B . Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies. Acta Oncol. 2016; 55(7):930-2. DOI: 10.3109/0284186X.2015.1120885. View

16.

Diamond E, Durham B, Ulaner G, Drill E, Buthorn J, Ki M . Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019; 567(7749):521-524. PMC: 6438729. DOI: 10.1038/s41586-019-1012-y. View

17.

Haroche J, Cohen-Aubart F, Emile J, Arnaud L, Maksud P, Charlotte F . Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2012; 121(9):1495-500. DOI: 10.1182/blood-2012-07-446286. View

18.

Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F . Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010; 116(20):4070-6. DOI: 10.1182/blood-2010-04-279240. View

19.

Cohen Aubart F, Roos-Weil D, Armand M, Marceau-Renaut A, Emile J, Duployez N . High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood. 2020; 137(4):485-492. PMC: 8555377. DOI: 10.1182/blood.2020005101. View

20.

Bentel J, Thomas M, Rodgers J, Arooj M, Gray E, Allcock R . Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation. BMJ Case Rep. 2017; 2017. PMC: 5534755. DOI: 10.1136/bcr-2017-219720. View